거래 명세서
Hikma has strong start to 2024, with continued momentum across all businesses. Full year guidance reiterated
25 년 2024 월 XNUMX 일 런던 - Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading ahead of its Annual General Meeting.
Riad Mishlawi, Hikma's CEO, said:
"Hikma has had a strong start to 2024, with continued growth and momentum across the Group. Our three businesses are performing well, underpinned by our strong commercial and operational capabilities. We are launching new products and expanding our manufacturing capacity, which will drive sustainable future growth."
그룹
The Group had a strong and encouraging start to the year, supported by all three business segments.
We expect Group revenue to grow in the range of 4% to 6% and for core operating profit to be in the range of $660 million to $700 million in 2024, in line with prior guidance.
주사제
Our global Injectables business has had a good start to the year. In the US, the breadth of our portfolio, new launches, and our new high speed filling lines are enabling us to capture new market opportunities. In Europe, we are benefitting from good demand for our own products and we continue to make progress in new markets. We are also seeing solid growth across our MENA markets, supported by our biosimilar portfolio and recent launches.
We have launched three products year-to-date in the US and are expanding our global manufacturing capacity, including strengthening our sterile manufacturing capabilities in MENA.
We continue to expect 2024 Injectables revenue to grow in the range of 6% and 8% and for core operating margin to be between 36% and 37%.
브랜드
Building on recent momentum, Branded has had a strong start to the year, supported by a growing product portfolio and our commercial and operational strength in the MENA region. We are seeing strong demand across our MENA markets and increased sales both for our portfolio of oncology medicines and for those medicines used to treat chronic illnesses.
In 2023 we became the second largest pharmaceutical company in MENA by sales1. We are investing in R&D to launch more complex and first-to-market products. We are also gaining market share in key therapeutic areas - we are the sixth largest supplier of new generation type II diabetes products and second largest for multiple sclerosis therapies2. We are investing in enhancing our manufacturing capacity and capabilities, strengthening our position as a local manufacturer and supplier of high-quality medicines with industry-leading global expertise.
For 2024, we continue to expect Branded revenue to grow in the mid- to high-single digits in constant currency, or low-single digits on a reported basis. Given the strong performance in the year to date, we now expect slight growth in reported core operating profit.
제네릭
Our Generics business is performing well. This reflects a robust performance from our broad product portfolio and recent launches. We are focusing on building a differentiated portfolio and pipeline for this business, as well as leveraging our state-of-the-art facility in Columbus, Ohio.
Last week, Hafrun Fridriksdottir was appointed as President of the Generics business. Hafrun brings more than 25 years of strong leadership and deep pharmaceutical industry experience to her new role, with a particular emphasis on research and development, successful pipeline expansion and new product introductions, making her well positioned to lead Hikma's Generics business in its next phase of growth.
We continue to expect Generics revenue to grow in the range of 3% to 5% in 2024. We expect 2024 core operating margin to be in the mid-teens, reflecting the increase in royalties payable on our authorised generic of sodium oxybate.
최종 배당금
Subject to approval at today's Annual General Meeting, we will be paying a final dividend of 47 cents per share. The final dividend brings the total dividend for the full year 2023 to 72 cents per share, an increase of 29% on 2022. This equates to a payout ratio of around 32%, which is above our historical range of 20% to 30%. We intend to progressively increase our dividend, with a payout ratio in the range of 30% to 40%, reflecting the Board's confidence in the long-term growth prospects for the Group and our ongoing commitment to return cash to shareholders.
We will announce our interim results for the six months ended 30 June 2024 on 8 August 2024.
자세한 정보
Hikma will hold a live Q&A conference call for sell-side analysts at 9:00am BST. A recording and transcript will be made available on the Company's website.
전화 회의를 통해 참여하려면 다음으로 전화하십시오.
영국(현지): +44 20 3936 2999
영국(수신자 부담): +44 800 358 1035
글로벌 전화 접속 번호
액세스 코드: 565272
-- 끝 --
문의 :
히크마(투자자)
수잔 링달 EVP, 전략 계획 및 글로벌 문제 | +44 (0)20 7399 2760/ +44 (0)7776 477050 |
가이 페더스톤 투자자 관계 이사 | +44 (0)20 3892 4389/ +44 (0)7795 896738 |
라얀 칼리세 선임 연구원, 투자자 관계 | +44 (0)20 7399 2788/ +44 (0)7970 709912 |
테네오(프레스) Doug Campbell / Rob Yates |
+44 (0)7753 136628/ +44 (0)7715 375443 |
히크마 소개
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (BBB-/안정적 S&P 및 BBB-/긍정적 Fitch 등급)
Hikma는 전 세계 수백만 명의 사람들이 매일 더 나은 건강을 누릴 수 있도록 돕습니다. 45년 이상 동안 우리는 고품질 의약품을 개발하여 이를 필요로 하는 사람들이 이용할 수 있도록 해왔습니다. 영국에 본사를 두고 있는 당사는 북미, 중동 및 북아프리카(MENA) 및 유럽 전역에 현지 지사를 두고 있는 글로벌 기업이며 고유한 통찰력과 전문 지식을 사용하여 최첨단 과학을 사람들의 삶을 변화시키는 혁신적인 솔루션으로 전환합니다. 살고있다. 우리는 고객과 고객이 아끼는 사람들을 위해 최선을 다하고 있으며 창의적으로 생각하고 실질적으로 행동함으로써 광범위한 브랜드 및 비브랜드 제네릭 의약품을 제공합니다. 우리의 9,100명의 동료들은 함께 모든 지역 사회를 풍요롭게 하는 더 건강한 세상을 만드는 데 도움을 주고 있습니다. 우리는 선도적인 라이센싱 파트너이며 벤처 캐피털 부문을 통해 전 세계 사람들에게 혁신적인 건강 기술을 제공하는 데 도움을 주고 있습니다. 자세한 내용은 다음을 방문하십시오. www.hikma.com
©2024 Hikma 제약 PLC. 판권 소유.
미래 예측 진술
Hikma cautions shareholders that any forward-looking statements or projections made by Hikma, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those risk factors described in the "Principal risks and uncertainties" section in Hikma's latest Annual Report. Where included, such statements have been made by or on behalf of Hikma in good faith based upon the knowledge and information available to the Directors on the date of this announcement. Accordingly, no assurance can be given that any particular expectation will be met and Hikma's shareholders are cautioned not to place undue reliance on any forward-looking statements. Other than in accordance with its legal or regulatory obligations (including under the UK Market Abuse Regulation and the UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), Hikma does not undertake to update any forward-looking statements contained in this announcement to reflect any changes in events, conditions or circumstances on which any such statement is based or to correct any inaccuracies which may become apparent in any such forward-looking statements.
[1] IQVIA MIDAS Pharma Index MAT Feb-2024. Retail + Hospital. Excluding Milks and diagnostics. Excluding Lebanon.
2 IQVIA MIDAS Pharma Index MAT Feb-2024. Retail + Hospital. Excluding Milks and diagnostics. Excluding Lebanon. Excluding F & G NFC1
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.